SCHEMBL14629947

SCHEMBL14629947

CONC(=O)CCN1CCNC1=O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGDS O60760 1/20 0.38
OPRM1 P35372 2/20 0.36
CREBBP Q92793 1/20 0.36
MEN1 O00255 2/20 0.35
FAAH O00519 1/20 0.35
NAAA Q02083 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RET P07949 1/20 0.35
KDR P35968 1/20 0.35
POLB P06746 2/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14629946 0.80 MAPT (0.35) KMT2AALDH1A1LMNAMEN1SMN1; SMN2
SCHEMBL6378864 0.76 ALDH1A1 (0.44) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6070489 0.74 KMT2A (0.44) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL26097101 0.73 TSHR (0.54) KMT2ARAB9AALDH1A1LMNAMEN1
SCHEMBL17428294 0.73 KMT2A (0.54) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL17431466 0.72 RAB9A (0.50) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL8198297 0.71 ALDH1A1 (0.43) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL8194555 0.71 ALDH1A1 (0.43) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL4575750 0.71 ALDH1A1 (0.43) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL4391703 0.71 KMT2A (0.43) KMT2ARAB9AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734507-B1 PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS ALLNEX IP S À R L (LU) 2017-05-31 EP claimed
US-20140179931-A1 Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas ALLNEX USA INC. (US) 2014-06-26 US claimed
EP-2734507-B1 PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS ALLNEX IP S À R L (LU) 2017-05-31 EP disclosed
US-9440928-B2 Process for the synthesis of N-substituted cyclic alkylene ureas Allnex IP S.ar.L. (LU) 2016-09-13 US disclosed
US-20140179931-A1 Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas ALLNEX USA INC. (US) 2014-06-26 US disclosed
EP-2734507-A1 PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS Allnex IP S.à.r.l. (LU) 2014-05-28 EP disclosed
WO-2013012995-A1 PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS CYTEC TECHNOLOGY CORP. (US) 2013-01-24 WO disclosed
EP-2548869-A1 Process for the Synthesis of N-substituted Cyclic Alkylene Ureas Cytec Technology Corp. (US) 2013-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179931-A1 Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas CA4, CA2, CDYL KMT2A 996/4885RAB9A 4534/4885ALDH1A1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.